Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lotiglipron Formulations in Overweight/Obese Adults
NCT05677867Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lotiglipron in obesity and Overweight (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve to Infinity, Area Under the Plasma Concentration-Time Profile From Time 0 to Last Quantifiable Concentration and 1 more. Started Jan 2023; status: completed.
02
Drugs
lotiglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05677867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677867.